Palifermin vs OGP
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and OGP (Osteogenic Growth Peptide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | OGP |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | Osteogenic Growth Peptide |
| Molecular Weight | 16.3 kDa | 1600 Da |
| Half-Life | 4–6 hours | N/A |
| Amino Acids | 140 | 14 |
| Typical Dose | 60 µg/kg/day | research-dependent low microgram range |
| Route | Intravenous | Subcutaneous/Local |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 80 |
| Research Status | Clinical | Pre-clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
OGP Benefits
- ✓stimulates osteoblast activity
- ✓supports fracture repair
- ✓may increase bone matrix deposition
- ✓may improve healing after injury
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
OGP Dosing
research-dependent microgram or nanomolar dosing|subcutaneous or local experimental delivery|cycle-dependent in studies
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
OGP Side Effects
- ⚠uncertain safety profile
- ⚠injection-site irritation
- ⚠theoretical endocrine effects
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
OGP
OGP has mostly preclinical literature showing effects on bone cell signaling, mineralization, and repair models. It is not as clinically established as teriparatide or BMPs, but it is a genuine peptide in the bone-regeneration literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.